Here are the 10-Q quarterly reports from Bone Biologics Corp (BBLG) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BBLG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BBLG filings page.
Bone Biologics Corp. reported a third-quarter 2026 net loss of $617,651, compared with $666,737 in the same 2025 period; nine-month net loss was $2,157,341 versus $2,424,348. Revenue was $0 in the comparative periods. Cash was $6,088,085 at September 30, 2026, and operating activities used $1,854,997 during the nine months ended September 30, 2026. Available cash is expected to fund operations through the second quarter of 2027, but these factors raise substantial doubt about the company's ability to continue as a going concern within one year after the financial statements are issued.
In July 2026, Bone Biologics sold 2,112,677 units in a private placement, receiving $2,639,667 in net proceeds after offering costs. Each unit included one pre-funded warrant, one Series F warrant and one Series G warrant. Nasdaq notified the company that its closing bid price did not meet the $1-per-share minimum for 30 consecutive business days; the compliance period runs through March 9, 2027. The Australian NB1 pilot clinical study is designed to evaluate up to 30 adults, and U.S. commercialization requires an FDA-approved pre-market approval (PMA) application.
Bone Biologics Corporation reported no revenue and a net loss of $1.54 million for the six months ended June 30 2026, an improvement from a $1.76 million loss a year earlier as total operating expenses declined 9.7% to $1.61 million. Research and development spending fell 26.8% to $450,344, largely due to timing of clinical trial activities, while general and administrative costs were roughly flat.
Cash totaled $4.03 million at June 30 2026, down from $5.33 million at year-end, with $1.32 million used in operating activities in the first half. Subsequent to quarter-end, the company completed a July 2026 private placement of pre-funded and common stock warrants, generating approximately $2.7 million in net proceeds and extending expected funding into the second quarter of 2027.
Management and the auditors state that recurring losses, an accumulated deficit of about $89.7 million, and limited capital resources raise substantial doubt about the company’s ability to continue as a going concern without additional financing. The company remains a clinical-stage medical device business focused on its NELL-1/DBM spinal fusion program, with ongoing pilot clinical work in Australia and significant future spending anticipated to support pivotal trials and regulatory approval.
Bone Biologics Corporation reported no revenue and a net loss of $765,988 for the three months ended March 31, 2026, an improvement from a $1,017,092 loss a year earlier. Research and development spending fell to $141,597 as clinical trial timing shifted, while general and administrative costs rose modestly to $663,457.
Cash was $4,530,040 at March 31, 2026, down from $5,334,322 at year-end, and operating cash outflow was $804,282. Management estimates operating expenditures of $5.4 million over the next twelve months and expects existing cash to fund operations into the fourth quarter of 2026, but the filing states there is “substantial doubt” about the company’s ability to continue as a going concern without additional financing.
Bone Biologics Corporation (BBLG) filed its Q3 2025 report, highlighting continued clinical-stage investment with no revenue and a narrower quarterly net loss. Net loss was $666,737 for the quarter and $2,424,348 for the nine months. Operating expenses fell year over year as R&D spending eased with clinical timing, while G&A was stable. Cash reached $6.05 million at September 30, 2025, up from $3.33 million at year-end, supported by financing.
The company completed a June 2025 public offering, issuing 793,750 shares and pre-funded warrants to purchase 456,250 shares, for net proceeds of $4,352,792, and issued 2,500,000 warrants at a $4.00 exercise price. It also raised $347,549 via its ATM program. As of November 14, 2025, shares outstanding were 1,795,260. Management disclosed substantial doubt about the company’s ability to continue as a going concern, citing cumulative losses of approximately $87.4 million, though available cash is expected to fund operations into the fourth quarter of 2026.